Skip to main content
GRI
NASDAQ Life Sciences

GRI Bio Reports Positive Phase 2a Data for IPF Drug GRI-0621, Extends Cash Runway

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$2.304
Mkt Cap
$3.266M
52W Low
$2.1
52W High
$80.36
52W Position info
9.7% above low
Off High info
97% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

GRI is trading near its 52-week low of $2.1 (9.7% above the low) on light trading volume (0.1× avg).

Summary

GRI Bio announced positive Phase 2a clinical data for its lead IPF drug, GRI-0621, showing improved tolerability and efficacy signals, while also extending its cash runway into Q2 2027.


Key Events · Financing and Capital Events · GRI

  • Positive Phase 2a Clinical Data for GRI-0621 in IPF

    The company reported that its lead candidate, GRI-0621, met its primary safety and tolerability endpoint in a Phase 2a trial for Idiopathic Pulmonary Fibrosis (IPF). Data showed zero cough, reduced dyspnea, no weight loss, and a 61% reduction in diarrhea compared to placebo, despite higher nintedanib use in the active arm. Exploratory pulmonary function showed a +99 mL FVC improvement overall, and +139 mL in the standard-of-care combination subset versus placebo + SOC at 12 weeks.

  • Extended Cash Runway into Q2 2027

    GRI Bio reported approximately $11.0 million in cash and cash equivalents as of March 31, 2026, which is expected to fund planned operations into the second quarter of 2027. This extension was partly supported by generating approximately $6.8 million in gross proceeds from its At-The-Market facility during Q1 2026, addressing the previously highlighted going concern warning.

  • Q1 2026 Financial Results

    The company reported a net loss of approximately $2.0 million for the quarter ended March 31, 2026, a reduction from $3.0 million in the same period of 2025. Research and development expenses decreased to $0.4 million due to the completion of the Phase 2a clinical trial in 2025.


Analysis · GRI · Life Sciences

This filing provides detailed positive Phase 2a clinical trial results for GRI-0621 in Idiopathic Pulmonary Fibrosis (IPF), demonstrating favorable safety, tolerability, and efficacy signals. For a micro-cap biotech, positive clinical data for a lead candidate is a significant de-risking event. Additionally, the company has extended its cash runway into Q2 2027, addressing the previously disclosed going concern warning and providing critical time for further development.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GRI was trading at $2.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.3M. The 52-week trading range was $2.10 to $80.36. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GRI - Latest Insights

GRI
Sep 28, 2026, 4:43 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $2.07
Real-time Price: $1.90 info
Change: -$0.170 (-8%) info
Market Cap: $4.001M info
GRI
Sep 08, 2026, 8:16 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.60
Real-time Price: $1.90 info
Change: -$0.700 (-27%) info
Market Cap: $4.001M info
GRI
Aug 24, 2026, 9:05 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.70
Real-time Price: $1.90 info
Change: +$0.1981 (+12%) info
Market Cap: $4.001M info
GRI
Aug 14, 2026, 7:44 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.88
Real-time Price: $1.90 info
Change: +$0.020 (+1%) info
Market Cap: $4.001M info
GRI
Jun 18, 2026, 4:50 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.90
Real-time Price: $1.90 info
Change: +$0.0005 (+0.03%) info
Market Cap: $4.001M info